TY  - GEN
AU  - Wang,Feng-Hua
AU  - Wang,Yun
AU  - Sun,Guo-Ping
AU  - Chen,Jian-Hua
AU  - Lin,Ying-Cheng
AU  - Liu,Wei
AU  - Zheng,Rong-Sheng
AU  - Chen,Jia
AU  - Zhang,He-Long
AU  - Lan,Hai-Tao
AU  - Qi,Jun
AU  - Liu,Yang-Qing
AU  - Deng,Yan-Ming
AU  - Zhao,Heng
AU  - Xiong,Jian-Ping
AU  - Xu,Qing
AU  - Jiang,Wen-Qi
AU  - Li,Yu-Hong
TI  - Efficacy and safety of recombinant human lymphotoxin-α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label, controlled, phase 2b trial
SN  - 1097-0142
PY  - 2017///1011
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Carcinoma, Squamous Cell
KW  - drug therapy
KW  - China
KW  - Cisplatin
KW  - administration & dosage
KW  - Disease-Free Survival
KW  - Esophageal Neoplasms
KW  - metabolism
KW  - Female
KW  - Fluorouracil
KW  - Humans
KW  - Lymphotoxin-alpha
KW  - adverse effects
KW  - Male
KW  - Middle Aged
KW  - Receptors, Tumor Necrosis Factor, Type II
KW  - blood
KW  - Recombinant Proteins
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
UR  - https://doi.org/10.1002/cncr.30845
ER  -